复方夏天无片联合氟桂利嗪治疗偏头痛的临床研究

Clinical study on Compound Xiatianwu Tablets combined with flunarizine in treatment of migraine

目的探讨复方夏天无片联合氟桂利嗪治疗偏头痛患者的临床疗效。方法选取南阳医学高等专科学校第一附属医院2016年1月—2017年1月收治的偏头痛患者161例,随机分成对照组(80例)和治疗组(81例)。对照组患者口服盐酸氟桂利嗪胶囊,2粒/次,2次/d;治疗组在对照组的基础上口服复方夏天无片,2片/次,3次/d。两组患者均治疗2个月。观察两组患者临床疗效和复发率,比较治疗前后两组患者头痛频率和平均持续时间,VAS评分和降钙素基因相关肽(CGRP)水平及不良反应情况。结果治疗后,对照组患者临床有效率为86.25%,显著低于治疗组的97.53%(P<0.05);治疗后,对照组复发率为15.00%,显著高于治疗组的3.70%(P<0.05)。治疗后,两组患者头痛发作次数和头痛平均持续时间均显著下降(P<0.05),且治疗组患者比对照组降低的更明显(P<0.05)。治疗后,两组患者VAS评分和CGRP血清水平均显著降低(P<0.05),且治疗组VAS评分和血清CGRP水平明显低于对照组(P<0.05)。治疗期间,对照组患者的不良反应发生率为13.75%,明显高于治疗组患者的3.70%,两组比较差异具有统计学意义(P<0.05)。结论复方夏天无片联合氟桂利嗪治疗偏头痛疗效显著,安全性高,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Compound Xiatianwu Tablets combined with flunarizine in treatment of migraine. Methods Patients（161 cases） with migraine in the First Affiliated Hospital of Nanyang Medical College from January 2016 to January 2017 were randomly divided into control（80 cases） and treatment（81 cases）. Patients in the control group were po administered with Flunarizine Hydrochloride Capsules, 2 grains/time, twice daily. Patients in the treatment group were po administered with Compound Xiatianwu Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy and recurrence rate was evaluated, and the frequency and average duration of headache, the VAS score and CGRP level, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.25%, which was significantly lower than 97.53% in the treatment group（P〈0.05）. After treatment, the recurrence rate in the control group was 15.00%, which was significantly higher than 3.70% in the treatment group（P〈0.05）. After treatment, the frequency and average duration of headache in two groups was significantly decreased（P〈0.05）. And the indexes in the treatment group were significantly lower than those in the control group（P〈0.05）. After treatment, the the VAS score and CGRP level in two groups was significantly decreased（P〈0.05）. And these indexes in the treatment group were significantly lower than those in the control group（P〈0.05）. During the treatment, the incidence of adverse reactions in the control group was 13.75%, which was significantly higher than 3.70% in the treatment group, with significant difference between two groups（P〈0.05）. Conclusion Compound Xiatianwu Tablets combined with flunarizine has significant clinical efficacy in treatment of migrainewith high safety, which has a certain clinical application value.